Non-Surgical Management of Urinary Incontinence.

IF 2.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Journal of the American Board of Family Medicine Pub Date : 2024-09-01 DOI:10.3122/jabfm.2023.230471R1
Ranna Al-Dossari, Monica Kalra, Julie Adkison, Bich-May Nguyen
{"title":"Non-Surgical Management of Urinary Incontinence.","authors":"Ranna Al-Dossari, Monica Kalra, Julie Adkison, Bich-May Nguyen","doi":"10.3122/jabfm.2023.230471R1","DOIUrl":null,"url":null,"abstract":"<p><p>Urinary incontinence management varies depending on the type of incontinence and severity of symptoms. Types of incontinence include stress (SUI), urge or overactive bladder (OAB), mixed, neurogenic, and overflow incontinence. First-line treatment for OAB and SUI is nonpharmacologic management. Behavioral therapy is first-line treatment for urge incontinence. Vaginal mechanical devices (cones, pessaries, and urethral plugs), pelvic floor muscle training, and electroacupuncture are recommended as first-line treatment for women with SUI. Biofeedback and electric muscle stimulation can be adjunctive therapy for SUI. Antimuscarinics and β-3 agonists can be used as adjective therapy for those with OAB who do not improve with behavioral therapy. β-3 agonists have less anticholinergic side effects compared with antimuscarinics for OAB. Adverse medication effects can often lead to discontinuation due to poor tolerability. Third-line therapies are for those who fail conservative and pharmacologic therapies and lack high-grade evidence. Neuromodulation, neurotoxin injections, vaginal laser therapy, and acupuncture are third-line in OAB management. Pharmacologic management with α-1-blockers is recommended as first-line treatment for moderate to severe overflow incontinence from BPH. 5-α reductase inhibitors can be used as an adjunct medication in those with refractory overflow incontinence symptoms and a PSA ≥ 1.5 mg/dL. Clean intermittent catheterization is first-line therapy for neurogenic bladder but can increase risk of catheter-associated urinary tract infection. Clinicians should assess type of incontinence, patient goals, side effect profile, and tolerability to determine an individualized treatment plan for each patient.</p>","PeriodicalId":50018,"journal":{"name":"Journal of the American Board of Family Medicine","volume":"37 5","pages":"909-918"},"PeriodicalIF":2.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Board of Family Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3122/jabfm.2023.230471R1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Urinary incontinence management varies depending on the type of incontinence and severity of symptoms. Types of incontinence include stress (SUI), urge or overactive bladder (OAB), mixed, neurogenic, and overflow incontinence. First-line treatment for OAB and SUI is nonpharmacologic management. Behavioral therapy is first-line treatment for urge incontinence. Vaginal mechanical devices (cones, pessaries, and urethral plugs), pelvic floor muscle training, and electroacupuncture are recommended as first-line treatment for women with SUI. Biofeedback and electric muscle stimulation can be adjunctive therapy for SUI. Antimuscarinics and β-3 agonists can be used as adjective therapy for those with OAB who do not improve with behavioral therapy. β-3 agonists have less anticholinergic side effects compared with antimuscarinics for OAB. Adverse medication effects can often lead to discontinuation due to poor tolerability. Third-line therapies are for those who fail conservative and pharmacologic therapies and lack high-grade evidence. Neuromodulation, neurotoxin injections, vaginal laser therapy, and acupuncture are third-line in OAB management. Pharmacologic management with α-1-blockers is recommended as first-line treatment for moderate to severe overflow incontinence from BPH. 5-α reductase inhibitors can be used as an adjunct medication in those with refractory overflow incontinence symptoms and a PSA ≥ 1.5 mg/dL. Clean intermittent catheterization is first-line therapy for neurogenic bladder but can increase risk of catheter-associated urinary tract infection. Clinicians should assess type of incontinence, patient goals, side effect profile, and tolerability to determine an individualized treatment plan for each patient.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
尿失禁的非手术治疗。
尿失禁的处理取决于尿失禁的类型和症状的严重程度。尿失禁的类型包括压力性尿失禁(SUI)、膀胱冲动或过度活动性尿失禁(OAB)、混合性尿失禁、神经性尿失禁和溢流性尿失禁。OAB和SUI的一线治疗是非药物治疗。行为疗法是急迫性尿失禁的一线治疗方法。阴道机械装置(阴道锥、子宫托和尿道塞)、盆底肌肉训练和电针被推荐作为SUI女性的一线治疗。生物反馈和肌肉电刺激可作为SUI的辅助治疗。抗蛇毒素和β-3激动剂可作为OAB患者的形容词治疗,行为治疗不能改善OAB。β-3激动剂与抗蛇毒素相比,抗胆碱能副作用较小。由于耐受性差,药物不良反应常常导致停药。三线治疗适用于那些保守和药物治疗失败且缺乏高级别证据的患者。神经调节、神经毒素注射、阴道激光治疗和针灸是治疗OAB的三线方法。α-1阻滞剂的药物管理被推荐作为BPH引起的中度至重度溢流性尿失禁的一线治疗。5-α还原酶抑制剂可作为难治性溢流失禁症状和PSA≥1.5 mg/dL的辅助用药。清洁间歇导尿是神经源性膀胱的一线治疗方法,但会增加导尿相关尿路感染的风险。临床医生应评估失禁类型、患者目标、副作用概况和耐受性,以确定每个患者的个性化治疗计划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.90
自引率
6.90%
发文量
168
审稿时长
4-8 weeks
期刊介绍: Published since 1988, the Journal of the American Board of Family Medicine ( JABFM ) is the official peer-reviewed journal of the American Board of Family Medicine (ABFM). Believing that the public and scientific communities are best served by open access to information, JABFM makes its articles available free of charge and without registration at www.jabfm.org. JABFM is indexed by Medline, Index Medicus, and other services.
期刊最新文献
A Retrospective Analysis of Soft Tissue Point-of-Care Ultrasound (POCUS) in Primary Care. Do No Harm? Rethinking Urine Drug Screens in Treatment of Opioid Use Disorder. Prostate Specific Antigen Ordering After Implementation of a Point-of-Care Reminder to Discuss Screening. Evaluation of the Need for Comprehensive Care for Patients with Cystic Fibrosis. Reimbursement and Policy Considerations of Point-of-Care Ultrasound (POCUS) in Rural Family Medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1